AR128124A1 - Células t cd4⁺ que expresan il-10 y receptores de antígenos quiméricos y usos de estos - Google Patents
Células t cd4⁺ que expresan il-10 y receptores de antígenos quiméricos y usos de estosInfo
- Publication number
- AR128124A1 AR128124A1 ARP220103606A ARP220103606A AR128124A1 AR 128124 A1 AR128124 A1 AR 128124A1 AR P220103606 A ARP220103606 A AR P220103606A AR P220103606 A ARP220103606 A AR P220103606A AR 128124 A1 AR128124 A1 AR 128124A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- express
- chimeric antigen
- cd4il
- antigen receptors
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 108010017550 Interleukin-10 Receptors Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000000735 allogeneic effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación proporciona una población de células CD4IL⁻¹⁰ / CAR (de dador único autólogo o alogénico y de polidadores alogénicos) generada al modificar genéticamente células T CD4⁺ para que expresen IL-10 y un receptor de antígeno quimérico. Además, se proporcionan métodos para generar las células CD4IL⁻¹⁰ / CAR y métodos para usar las células CD4IL⁻¹⁰ / CAR para la inmunotolerización, para tratar la FvHD, para trasplante de células y órganos, para el cáncer y para otros trastornos autoinmunitarios e inflamatorios.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163295491P | 2021-12-30 | 2021-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128124A1 true AR128124A1 (es) | 2024-03-27 |
Family
ID=85172951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103606A AR128124A1 (es) | 2021-12-30 | 2022-12-27 | Células t cd4⁺ que expresan il-10 y receptores de antígenos quiméricos y usos de estos |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR128124A1 (es) |
TW (1) | TW202334400A (es) |
WO (1) | WO2023129929A1 (es) |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
KR20230133410A (ko) | 2010-12-09 | 2023-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
EA201391059A1 (ru) | 2011-01-18 | 2014-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции для лечения рака и способы их применения |
EP2756521A4 (en) | 2011-09-16 | 2015-04-22 | Univ Pennsylvania | RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER |
RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
EP3626741A1 (en) | 2013-02-20 | 2020-03-25 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
HUE054588T2 (hu) | 2014-04-07 | 2021-09-28 | Novartis Ag | Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával |
AU2016225012B2 (en) | 2015-02-27 | 2020-09-03 | Kevin Chen | Chimeric antigen receptors (CARS) targeting hematologic malignancies, compositions and methods of use thereof |
EP3988106A1 (en) | 2015-03-13 | 2022-04-27 | Ospedale San Raffaele S.r.l. | Il-10-producing cd4+ t cells and uses thereof |
GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
EP3347375B1 (en) | 2015-09-10 | 2020-12-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-cd276 chimeric antigen receptors |
JP7208010B2 (ja) | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
CN117298260A (zh) | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
DK3757120T3 (da) | 2016-10-04 | 2022-07-25 | Prec Biosciences Inc | Co-stimulerende domæner til anvendelse i genetisk modificerede celler |
US20220233588A1 (en) * | 2017-06-30 | 2022-07-28 | Cellectis | Cellular immunotherapy for repetitive administration |
CN111183156A (zh) | 2017-07-31 | 2020-05-19 | 莱蒂恩技术公司 | 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法 |
EP3810189A1 (en) * | 2018-06-19 | 2021-04-28 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
WO2020010235A1 (en) | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
AU2020245329A1 (en) * | 2019-03-26 | 2021-10-28 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed Tregs expressing CARs |
KR20240049813A (ko) * | 2021-08-24 | 2024-04-17 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 향상된 암 면역치료법을 위한 il-10 발현 세포 |
-
2022
- 2022-12-27 WO PCT/US2022/082431 patent/WO2023129929A1/en unknown
- 2022-12-27 AR ARP220103606A patent/AR128124A1/es unknown
- 2022-12-27 TW TW111150212A patent/TW202334400A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW202334400A (zh) | 2023-09-01 |
WO2023129929A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ruella et al. | Next-generation chimeric antigen receptor T-cell therapy: going off the shelf | |
WO2020092854A3 (en) | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) | |
EA201992469A1 (ru) | Антигенспецифические иммунные эффекторные клетки | |
AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
CL2020001151A1 (es) | Receptores de antígenos quiméricos específicos para el antígeno de maduración de células b y polinucleótidos que codifican los mismos. | |
CL2021002147A1 (es) | Células asesinas naturales (nk) modificadas para inmunoterapia | |
CO2020001491A2 (es) | Molécula de polipéptido con especificidad dual mejorada | |
MX2018005618A (es) | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. | |
CU20180109A7 (es) | Métodos y composiciones para transducir linfocitos y expansión regulada de los mismos | |
AR120563A1 (es) | Receptores de antígeno quimérico cd19 y cd22 y sus usos | |
ES2672895T3 (es) | Generación de células T específicas de antígeno | |
CU20170023A7 (es) | Anticuerpos y receptores de antígeno quiméricos específicos para cd19 | |
CO2017000510A2 (es) | Constructos de car | |
DOP2011000114A (es) | compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas | |
PE20211662A1 (es) | Receptores que ofrecen coestimulacion especifica para terapia adoptiva de celulas | |
BR112015023701A2 (pt) | células t redirecionadas de receptor de antígeno quimérico específico cd123 e métodos de uso | |
MX2021010670A (es) | Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia. | |
MX2018013959A (es) | Metodos para tratar enfermedad autoinmune usando celulas t alogenicas. | |
MX2019012360A (es) | Composiciones y metodos mejorados de celulas t. | |
EA202091982A1 (ru) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии | |
EA202190573A1 (ru) | Композиции и способы перепрограммирования tcr с применением гибридных белков | |
RU2021132734A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
CO2022000402A2 (es) | Uso de linfocitos t con receptor de antígeno quimérico e inhibidores de linfocitos citolíticos naturales para el tratamiento del cáncer | |
AR102092A1 (es) | Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii) | |
BR112022002955A2 (pt) | Células imunes para terapias de células adotivas |